Home > Lower-risk Myelodysplastic Syndrome > Diagnostics/Identifying appropriate patients

In this section:

Identifying Appropriate Patients

In transfusion-dependent, lower-risk MDS

Guidelines Recommend Chelating Patients At Risk of Iron Toxicity

Approximately two-thirds of patients with myelodysplastic syndrome initially present with lower-risk disease. International guidelines recommend iron chelation for these patients once their transfusion therapy is underway.1,2,3

See the National Comprehensive Cancer Network Guidelines See the Myelodysplastic Syndromes Foundation Guidelines

Click on the green content in the chart below to learn more about each step

Identify Your Patients Who Will Benefit From Iron Chelation2-9
Identify Patients Who Will Benefit from Iron Chelation

Available for use online or as a downloadable version, the IPSS Calculator can help you determine the appropriate risk level of your MDS patients based on international consensus guidelines.

Learn more

EXJADE reduces LIC and serum ferritin in transfused patients with lower-risk myelodyspastic syndrome.

Learn more